A new Clonostachys sp. ZBS49 filamentous fungus with high production of betulinic acid and its inhibitory effect on liver cancer cells
Li Geng,
No information about this author
Jiale Cui,
No information about this author
Changyixin Xiao
No information about this author
et al.
Research Square (Research Square),
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 11, 2025
Abstract
Background
Triterpenoid
compounds
such
as
betulinic
acid
(BA)
and
oleanolic
(OA)
exhibit
considerable
pharmacological
activities.
However,
their
current
production
primarily
relies
on
plant
extraction
chemical
synthesis,
methods
that
are
often
plagued
by
low
efficiency,
complex
processes,
environmental
concerns.
Microbial-based
synthesis
has
emerged
one
of
the
most
effective
approaches
for
producing
BA
OA.
Results
This
study
presented
first
identification
filamentous
fungal
strains
efficiently
synthesizing
both
The
strain
ZBS49
is
a
newly
identified
species
Clonostachys
isolated
from
Gleditsia
japonica
Miq.
(showing
99.82%
sequence
identity),
produced
47.7
mg/L
BA.
XJ1-1,
characterized
Colletotrichum
gloeosporioides
Cannabis
sativa
L.,
yielded
65.76
After
optimizing
culture
medium
cultivation
conditions,
yields
XJ1-1
increased
to
288.97
86.14
mg/L,
representing
improvements
506%
31%,
respectively.
Furthermore,
we
discovered
extract
significantly
inhibited
hepatocellular
cancer
cells
(SMMC-7721
HepG2)
in
dose-dependent
manner,
with
minimum
inhibitory
concentration
70
µM.
Genomic
analysis
sp.
elucidated
presence
16
putative
genes
was
related
triterpenoid
biosynthesis
6
distinct
terpene
biosynthetic
gene
clusters.
Among
145
CYP450,
5
involved
C-28
oxidation
were
predicted.
Conclusions
research
underscores
effectiveness
fungi
biotechnological
platform
efficient
its
derivatives,
highlighting
potential
applications
therapy.
these
findings
provide
valuable
genetic
resources
establish
robust
technical
theoretical
framework
utilizing
microbial
triterpenoids.
Language: Английский
Nanoparticle-mediated delivery of herbal-derived natural products to modulate immunosenescence-induced drug resistance in cancer therapy: a comprehensive review
Lichang Yang,
No information about this author
Wei Wu,
No information about this author
Jing Yang
No information about this author
et al.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: April 28, 2025
Immunosenescence,
the
age-associated
decline
of
immune
system,
is
pivotal
in
fostering
drug
resistance
within
tumor
microenvironment
(TME).
The
accumulation
senescent
cells
and
release
pro-inflammatory
senescence-associated
secretory
phenotype
(SASP)
factors
create
a
milieu
that
supports
survival
undermines
therapeutic
efficacy.
Traditional
cancer
treatments
often
fail
to
address
this
underlying
issue,
leading
suboptimal
outcomes.
This
article
proposes
an
innovative
strategy
overcome
immunosenescence-induced
through
nanoparticle-mediated
delivery
herbal-derived
natural
products
(HDNPs),
which
possess
senolytic
immunomodulatory
properties
capable
clearing
rejuvenating
function.
Nanoparticle
systems
enhance
these
compounds’
stability,
bioavailability,
targeted
TME
cells.
By
harnessing
synergistic
effects
HDNPs
nanotechnology,
approach
offers
novel
multifaceted
solution
therapy.
It
holds
potential
restore
surveillance,
reduce
pro-survival
signaling
cells,
efficacy
conventional
treatments.
paradigm
shift
emphasizes
importance
addressing
immunosenescence
as
target
paves
way
for
more
effective
personalized
interventions.
Language: Английский